Synthaverse SA GPW:SVE:
RECEIVES MARKETING AUTHORIZATION FOR ONKO BCG MEDICINAL PRODUCT IN ECUADOR
Synthaverse Receives Marketing Authorization For Onko BCG Medicinal Product In Ecuador
Earlier from Synthaverse Spolka Akcyjna
- Synthaverse Gets Marketing Authorization For Onko BCG In Serbia
- Synthaverse Appoints Artur Chodkowski As CEO
- Synthaverse Q3 Net Loss 7.7 Million Zlotys
- Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands